Introduction: Cardiac amyloidosis is an infiltrative cardiomyopathy with high morbidity and mortality, frequently presenting as heart failure (HF) with preserved left ventricular ejection fraction (LVEF). In transthyretin cardiac amyloidosis (ATTR-CM), early recognition of clinical red flags is essential. Scintigraphy with 99mTc-labelled pyrophosphate (99mTc-PYP) is a key diagnostic tool. Tafamidis, a transthyretin stabiliser, has demonstrated efficacy in slowing disease progression.
Objective: To describe the clinical characteristics and outcomes of patients diagnosed with ATTR-CM by 99mTc-PYP scintigraphy, analysing the main diagnostic “red flags”, treatment decisions, and clinical evolution.
Methods: A retrospective analysis was conducted on 100 patients referred for 99mTc-PYP scintigraphy between January and October 2022 due to suspected ATTR-CM. Of the 30 positive scans, 29 were confirmed ATTR-CM (excluding one AL amyloidosis case). Clinical data and therapeutic decisions were assessed.